{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:34:17Z","timestamp":1769157257339,"version":"3.49.0"},"reference-count":84,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mem. Inst. Oswaldo Cruz"],"DOI":"10.1590\/0074-02760240115","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:46:16Z","timestamp":1729511176000},"source":"Crossref","is-referenced-by-count":2,"title":["Epoxy-a-lapachone in nanosystem: a prototype drug for leishmaniasis assessed in the binomial BALB\/c - Leishmania (Leishmania) amazonensis"],"prefix":"10.1590","volume":"119","author":[{"given":"Juliana Figueiredo","family":"Peixoto","sequence":"first","affiliation":[{"name":"Universidade Cat\u00f3lica de Petr\u00f3polis,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Filipe","family":"Gon\u00e7alves-Oliveira","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geovane","family":"Dias-Lopes","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil; Universidade do Estado do Rio de Janeiro,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Souza-Silva","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil; Universidade Igua\u00e7u,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-426X","authenticated-orcid":false,"given":"Carlos Roberto","family":"Alves","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Oswaldo Cruz-Fiocruz,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","year":"2007"},{"key":"ref2","year":"2024"},{"key":"ref3","year":"2019"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/DDDT.S146521","article-title":"Leishmaniasis in humans drug or vaccine therapy?","volume":"12","author":"Ghorbani M","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"ref5","first-page":"68","article-title":"Pancreatic toxicity as an adverse effect induced by meglumine antimoniate therapy in a clinical trial for cutaneous leishmaniasis","volume":"58","author":"Lyra MR","year":"2016","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"ref6","first-page":"28","article-title":"An overview of the treatment of cutaneous leishmaniasis","volume":"9","author":"Garza-Tovar TF","year":"2020","journal-title":"Fac Rev"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1590\/abd1806-4841.20198388","article-title":"American tegumentary leishmaniasis severe side effects of pentavalent antimonial in a patient with chronic renal failure","volume":"94","author":"Marques SA","year":"2019","journal-title":"An Bras Dermatol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.trstmh.2006.03.009","article-title":"Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives","author":"Croft SL","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An update on pharmacotherapy for leishmaniasis","volume":"16","author":"Sundar S","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.jddst.2020.101664","article-title":"A review of current treatments strategies based on paromomycin for leishmaniasis","volume":"57","author":"Matos APS","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-9145-7_5","article-title":"In silico target druggability assessment from structural to systemic approaches","volume":"1953","author":"Trosset JY","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.3390\/molecules26123537","article-title":"In silico insights into the mechanism of action of epoxy-a-lapachone and epoxymethyl-lawsone in Leishmania spp","volume":"26","author":"Peixoto JF","year":"2021","journal-title":"Molecules"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.exppara.2014.10.002","article-title":"Evidence for leishmanicidal activity of the naphthoquinone derivative epoxy-a-lapachone","volume":"147","author":"Souza-Silva F","year":"2014","journal-title":"Exp Parasitol"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.04742-14","article-title":"Epoxy-a-lapachone has in vitro and in vivo anti-Leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite","volume":"59","author":"Souza-Silva F","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","first-page":"9840210","article-title":"Evidence for tissue toxicity in BALB\/c exposed to a long-term treatment with oxiranes compared to meglumine antimoniate","volume":"2017","author":"Oliveira LFG","year":"2017","journal-title":"Biomed Res Int"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3390\/molecules23040864","article-title":"Antileishmanial activity of 2-Methoxy-4H-spiro-[naphthalene-1,2'-oxiran]-4-one (Epoxymethoxy-lawsone) a promising new drug candidate for leishmaniasis treatment","volume":"23","author":"Oliveira LFG","year":"2018","journal-title":"Molecules"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpddr.2019.08.002","article-title":"The combination therapy of meglumine antimoniate and oxiranes (epoxy-a-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis","volume":"10","author":"Gon\u00e7alves-Oliveira LF","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"111660","DOI":"10.1016\/j.ejmech.2019.111660","article-title":"Multi-target drugs active against leishmaniasis a paradigm of drug repurposing","volume":"183","author":"Braga SS","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/AAC.02834-14","article-title":"Ascorbate peroxidase, a key molecule regulating amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"58","author":"Kumar A","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1073\/pnas.1117280109","article-title":"Amphotericin primarily kills yeast by simply binding ergosterol","volume":"109","author":"Gray KC","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1128\/AAC.00030-11","article-title":"Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"56","author":"Purkait B","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bbrc.2010.07.099","article-title":"Amphotericin B inhibits entry of Leishmania donovani into primary macrophages","volume":"399","author":"Paila YD","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"1-2","key":"ref23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2011.11.023","article-title":"A novel mechanism for an old drug amphotericin B in the treatment of visceral leishmaniasis","volume":"416","author":"Chattopadhyay A","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"39","key":"ref24","doi-asserted-by":"crossref","first-page":"37561","DOI":"10.1074\/jbc.M306137200","article-title":"The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism","volume":"278","author":"Sau K","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1086\/315835","article-title":"Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human monocytic cell line THP-1","volume":"182","author":"Rogers PD","year":"2000","journal-title":"J Infect Dis"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1590\/S0074-02762011000400021","article-title":"Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes","volume":"106","author":"Marinho FA","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"ref27","first-page":"442","article-title":"Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum","volume":"15","author":"Khademvatan S","year":"2011","journal-title":"Braz J Infect Dis"},{"issue":"1","key":"ref28","first-page":"e01614","article-title":"Mechanism of action of miltefosine on Leishmania donovani involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent plasma membrane Ca2+ channel","volume":"62","author":"Pinto-Martinez AK","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1128\/AAC.01415-06","article-title":"Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes","volume":"51","author":"Luque-Ortega JR","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"7146","DOI":"10.4049\/jimmunol.0803859","article-title":"Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response","volume":"182","author":"Wadhone P","year":"2009","journal-title":"J Immunol"},{"issue":"13","key":"ref31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.2174\/0929867311320130004","article-title":"Polypharmacology in a single drug multitarget drugs","volume":"20","author":"Bolognesi ML","year":"2013","journal-title":"Curr Med Chem"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/17460441.2018.1413089","article-title":"Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery","volume":"13","author":"Ravikumar B","year":"2018","journal-title":"Expert Opin Drug Discov"},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17460441.2020.1767063","article-title":"An up-to-date overview of computational polypharmacology in modern drug discovery","volume":"15","author":"Chaudhari R","year":"2020","journal-title":"Expert Opin Drug Discov"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202200190","article-title":"Advances in computational polypharmacology","volume":"41","author":"Feldmann C","year":"2022","journal-title":"Mol Inform"},{"issue":"19","key":"ref35","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology challenges and opportunities in drug discovery","volume":"57","author":"Anighoro A","year":"2014","journal-title":"J Med Chem"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/acs.jmedchem.8b00760","article-title":"Polypharmacology by design a medicinal chemist's perspective on multitargeting compounds","volume":"62","author":"Proschak E","year":"2019","journal-title":"J Med Chem"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay RR","year":"2018","journal-title":"Clin Transl Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fchem.2020.00176","article-title":"A Definition of \"Multitargeticity\" identifying potential multitarget and selective ligands through a vector analysis","volume":"8","author":"S\u00e1nchez-Tejeda JF","year":"2020","journal-title":"Front Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"122864","DOI":"10.1016\/j.ijpharm.2023.122864","article-title":"Development of a microemulsion loaded with epoxy-a-lapachone against Leishmania (Leishmania) amazonensis murine infection","volume":"636","author":"Peixoto JF","year":"2023","journal-title":"Int J Pharm"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cocis.2012.06.001","article-title":"Microemulsions as delivery systems","volume":"17","author":"Fanun M","year":"2012","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3390\/nano10091657","article-title":"Microemulsion microstructure(s) a tutorial review","volume":"10","author":"Tartaro G","year":"2020","journal-title":"Nanomaterials (Basel)"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/adt.2022.119","article-title":"Pharmaceutical methods for enhancing the dissolution of poorly water-soluble drugs","volume":"21","author":"Mahmood T","year":"2023","journal-title":"Assay Drug Dev Technol"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10717544.2014.898347","article-title":"Transdermal microemulsions of Boswellia carterii Bird formulation, characterization and in vivo evaluation of anti-inflammatory activity","volume":"22","author":"Mostafa DM","year":"2015","journal-title":"Drug Deliv"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10717544.2014.950768","article-title":"Characterization and evaluation of self-nanoemulsifying sustained-release pellet formulation of ziprasidone with enhanced bioavailability and no food effect","volume":"23","author":"Miao Y","year":"2016","journal-title":"Drug Deliv"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"394264","DOI":"10.1155\/2014\/394264","article-title":"Nanotechnology-applied curcumin for different diseases therapy","volume":"2014","author":"Ghalandarlaki N","year":"2014","journal-title":"Biomed Res Int"},{"issue":"39","key":"ref46","doi-asserted-by":"crossref","first-page":"66680","DOI":"10.18632\/oncotarget.19164","article-title":"Nanoformulations of curcumin an emerging paradigm for improved remedial application","volume":"8","author":"Gera M","year":"2017","journal-title":"Oncotarget"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3762\/bjnano.15.4","article-title":"Curcumin-loaded nanostructured systems for treatment of leishmaniasis a review","volume":"15","author":"Dourado D","year":"2024","journal-title":"Beilstein J Nanotechnol"},{"issue":"10","key":"ref48","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.drudis.2017.06.004","article-title":"Leishmaniasis drug discovery recent progress and challenges in assay development","volume":"22","author":"Zulfiqar B","year":"2017","journal-title":"Drug Discov Today"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.vetpar.2008.09.015","article-title":"Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis","volume":"158","author":"Pereira BA","year":"2008","journal-title":"Vet Parasitol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13071-016-1413-9","article-title":"Study of Leishmania pathogenesis in mice experimental considerations","volume":"9","author":"Loeuillet C","year":"2016","journal-title":"Parasit Vectors"},{"key":"ref51","series-title":"Leishmanioses do continente Americano","volume-title":"Modelos de estudo para o desenvolvimento de drogas anti-Leishmania","author":"Soares ROA","year":"2014"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"100525","DOI":"10.1016\/j.ijpddr.2024.100525","article-title":"Efficacy of the treatment using a microemulsion loaded with epoxy-a-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis","volume":"24","author":"Peixoto JF","year":"2024","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"4","key":"ref53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/tmi.13210","article-title":"American tegumentary leishmaniasis in Brazil a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment","volume":"24","author":"Carvalho SH","year":"2019","journal-title":"Trop Med Int Health"},{"key":"ref54","first-page":"684","article-title":"Um novo processo para a obten\u00e7\u00e3o do antimoniato de meglumina, visando a produ\u00e7\u00e3o do medicamento gen\u00e9rico","volume":"7","author":"Carvalho AS","year":"2015","journal-title":"Rev Virtual Quim"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/aoc.425","article-title":"Pentavalent organoantimonial derivatives two simple and efficient synthetic methods for meglumine antimonate","volume":"17","author":"Demicheli C","year":"2003","journal-title":"Appl Organomet Chem"},{"issue":"8","key":"ref56","first-page":"e00539","article-title":"Efficacy of meglumine antimoniate in a low polymerization state orally administered in a murine model of visceral leishmaniasis","volume":"62","author":"Kato KC","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184777","article-title":"Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis a systematic review","volume":"12","author":"Brito NC","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"ref58","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760180200","article-title":"Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis a single arm, open label, phase II clinical trial","volume":"113","author":"Ramalho DB","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"7","key":"ref59","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/molecules14072317","article-title":"Pentavalent antimonials new perspectives for old drugs","volume":"14","author":"Fr\u00e9zard F","year":"2009","journal-title":"Molecules"},{"issue":"4","key":"ref60","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jinorgbio.2007.10.010","article-title":"New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate","volume":"102","author":"Fr\u00e9zard F","year":"2008","journal-title":"J Inorg Biochem"},{"issue":"3","key":"ref61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/clinids\/18.3.381","article-title":"Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala","volume":"18","author":"Arana BA","year":"1994","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref62","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/513776","article-title":"Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis","volume":"25","author":"Llanos-Cuentas A","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"2","key":"ref63","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/clinids\/24.2.165","article-title":"Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate","volume":"24","author":"Martinez S","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"Arevalo I","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ref65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000491","article-title":"First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony","volume":"3","author":"Miranda-Verastegui C","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"ref66","year":"2010"},{"key":"ref67","year":"2022"},{"issue":"12","key":"ref68","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00284-022-03075-1","article-title":"Development, characterization, and in vitro biological performance of amphotericin b and terbinafine microemulsions against Leishmania major","volume":"79","author":"Baharvandi Z","year":"2022","journal-title":"Curr Microbiol"},{"issue":"7","key":"ref69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1208\/s12249-022-02435-1","article-title":"Evaluation of the efficacy of amphotericin b and terbinafine microemulsions and their combination on cutaneous leishmaniasis and comparison with the conventional drug form in BALB\/c mice","volume":"23","author":"Baharvandi Z","year":"2022","journal-title":"AAPS PharmSciTech"},{"issue":"6","key":"ref70","first-page":"1","article-title":"Could combination chemotherapy be more effective than monotherapy in the treatment of visceral leishmaniasis A systematic review of preclinical evidence","volume":"149","author":"Bastos DSS","year":"2022","journal-title":"Parasitology"},{"issue":"4","key":"ref71","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bjid.2013.11.013","article-title":"Kidney involvement in leishmaniasis - a review","volume":"18","author":"Silva Jr GB","year":"2014","journal-title":"Braz J Infect Dis"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2369-13-44","article-title":"Renal function evaluation in patients with American cutaneous leishmaniasis after specific treatment with pentavalent antimonial","volume":"13","author":"Oliveira RA","year":"2012","journal-title":"BMC Nephrol"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1590\/S0036-46651999000100007","article-title":"Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis","volume":"41","author":"Rodrigues ML","year":"1999","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"issue":"2","key":"ref74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"Oliveira LF","year":"2011","journal-title":"Acta Trop"},{"issue":"3","key":"ref75","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1258\/td.2008.080369","article-title":"Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis a report of 13 cases in the southwestern region of Brazil","volume":"39","author":"Oliveira AL","year":"2009","journal-title":"Trop Doct"},{"issue":"7","key":"ref76","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it","volume":"12","author":"Sun D","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry new estimates of R&D costs","volume":"47","author":"DiMasi JA","year":"2016","journal-title":"J Health Econ"},{"issue":"20","key":"ref78","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMp1500848","article-title":"The $ 2 6 billion pill -- methodologic and policy considerations","volume":"372","author":"Avorn J","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"ref79","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.bjid.2023.102743","article-title":"Epoxy-a-lapachone (2,2-Dimethyl-3,4-dihydro-spiro[2H-naphtho[2,3-b]pyran-10,2'-oxirane]-5(10H)-one) a promising molecule to control infections caused by protozoan parasites","volume":"27","author":"Peixoto JF","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"ref80"},{"issue":"1","key":"ref81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-022-05581-4","article-title":"The pipeline for drugs for control and elimination of neglected tropical diseases 1. Anti-infective drugs for regulatory registration","volume":"16","author":"Pfarr KM","year":"2023","journal-title":"Parasit Vectors"},{"issue":"5","key":"ref82","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/13543776.2022.2045948","article-title":"Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis a patent review from 1998 to 2021","volume":"32","author":"Imran M","year":"2022","journal-title":"Expert Opin Ther Pat"},{"issue":"19","key":"ref83","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle A","year":"2020","journal-title":"J Med Chem"},{"key":"ref84","year":"2023"}],"container-title":["Mem\u00f3rias do Instituto Oswaldo Cruz"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0074-02762024000100853&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:46:36Z","timestamp":1729511196000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0074-02762024000100853&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":84,"alternative-id":["S0074-02762024000100853"],"URL":"https:\/\/doi.org\/10.1590\/0074-02760240115","relation":{},"ISSN":["1678-8060","0074-0276"],"issn-type":[{"value":"1678-8060","type":"electronic"},{"value":"0074-0276","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e240115"}}